1. Multiplexing fluorogenic esterase-based viability assay with luciferase assays
- Author
-
Kenji Ohgane, Hiromasa Yoshioka, and Yuichi Hashimoto
- Subjects
Lysis ,Clinical Biochemistry ,Cell ,010501 environmental sciences ,Esterase ,01 natural sciences ,03 medical and health sciences ,Biochemistry, Genetics and Molecular Biology ,medicine ,Luciferase ,Multiplex ,Viability assay ,lcsh:Science ,Bradford protein assay ,ComputingMethodologies_COMPUTERGRAPHICS ,030304 developmental biology ,0105 earth and related environmental sciences ,0303 health sciences ,Reporter gene ,Chemistry ,CytoRed-luciferase multiplex assay ,Medical Laboratory Technology ,Multiplex assay ,medicine.anatomical_structure ,CytoRed ,Viability ,Biochemistry ,Fluorogenic substrate ,lcsh:Q - Abstract
Graphical abstract, Luciferase-based reporter assays are one of the most common cell-based screening formats for drug discovery, and simultaneous evaluation of the cytotoxic effect of test compounds is of great value in reducing false-positives. Here we share a multiplex assay protocol that allows sequential measurement of cell viability (cell number) and luciferase activity of the same sample in a multi-well-plate format. The viability assay employs a fluorogenic esterase substrate, CytoRed. • This protocol allows sequential measurement of endogenous esterase activity (as a surrogate for cell number) and then luciferase activity in a single sample. • The protocol eliminates the need for parallel viability assay or protein assay using separate aliquots of the lysate. • This protocol is especially useful for assays with cells stably expressing a luciferase construct, for which co-transfection of another reporter gene is not a viable option.
- Published
- 2019